TY  - BOOK
AU  - Ben-Dor, Itsik
AU  - Case, Brian C
AU  - Forrestal, Brian J
AU  - Hahm, Joshua
AU  - Musallam, Anees
AU  - Rogers, Toby
AU  - Satler, Lowell F
AU  - Torguson, Rebecca
AU  - Waksman, Ron
AU  - Wang, Yanying
AU  - Yerasi, Charan
TI  - MitraClip 30-Day Readmissions and Impact of Early Discharge: An Analysis from the Nationwide Readmissions Database 2016
SN  - 1878-0938
PY  - 2020///
KW  - *Heart Valve Prosthesis
KW  - *Heart Valve Prosthesis Implantation/is [Instrumentation]
KW  - *Length of Stay
KW  - *Mitral Valve Insufficiency/su [Surgery]
KW  - *Mitral Valve/su [Surgery]
KW  - *Patient Discharge
KW  - *Patient Readmission
KW  - Aged
KW  - Aged, 80 and over
KW  - Databases, Factual
KW  - Feasibility Studies
KW  - Female
KW  - Heart Valve Prosthesis Implantation/ae [Adverse Effects]
KW  - Heart Valve Prosthesis Implantation/td [Trends]
KW  - Humans
KW  - Length of Stay/td [Trends]
KW  - Male
KW  - Mitral Valve Insufficiency/dg [Diagnostic Imaging]
KW  - Mitral Valve Insufficiency/pp [Physiopathology]
KW  - Mitral Valve/dg [Diagnostic Imaging]
KW  - Mitral Valve/pp [Physiopathology]
KW  - Patient Discharge/td [Trends]
KW  - Patient Readmission/td [Trends]
KW  - Prosthesis Design
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
N1  - Available in print through MWHC library: 2002 - present
N2  - BACKGROUND/PURPOSE: Edge-to-edge mitral valve repair (MVR) using the MitraClip (Abbott Vascular, Santa Clara, CA), is now labeled for patients with degenerative and functional mitral regurgitation. Because this is a minimally invasive transcatheter procedure, patients are commonly discharged early post-procedure, yet rates and causes of early readmissions are unknown. This study aimed to evaluate underlying causes and trends of 30-day readmissions using the 2016 US Nationwide Readmissions Database (NRD) in patients discharged early after MVR with MitraClip; CONCLUSIONS: Early discharge post-MitraClip treatment is feasible, safe, and associated with low readmission rates as compared to all MitraClip procedures performed. Special considerations for early discharge should apply to postprocedural complications and patients with heart failure, the most common readmission causes, as these may require longer stays post-procedure; METHODS/MATERIALS: We identified all patients who received a MitraClip in 2016 and then identified a cohort of patients who were discharged early (<48 h). Next, any admission within 30 days of the index procedure was identified; RESULTS: Our analysis included 3858 MitraClip patients. The overall 30-day readmission rate was 13.5%. A total of 2341 patients (61%) were discharged early. The readmission rate among the early discharge cohort was 10.1% (233/2314). The readmission rate among the early discharge cohort was 10.1% (233/2314). The major causes of readmission were heart failure (27.5%), infections (15.5%), and postprocedural complications (6.9%); SUMMARY: This study aimed to evaluate underlying causes and trends of 30-day readmissions using the US Nationwide Readmissions Database (NRD) 2016 dataset in patients discharged early after mitral valve repair with MitraClip. The overall 30-day readmission rate during this period was 13.5%; the readmission rate among patients discharged early (<48 h) was 10.1%. Early discharge post-MitraClip treatment is feasible and safe and is associated with low readmission rates. Copyright (c) 2020. Published by Elsevier Inc
UR  - https://dx.doi.org/10.1016/j.carrev.2020.04.004
ER  -